skip to the content

Clinical Trials

Rheumatoid Arthritis Study

A Partially Blinded, Randomized, Multi-Center, Phase IV Trial to Evaluated Mechanism of Action Of Anti-TNF Agents in Rheumatoid Arthritis

Protocol ID

09-167

Protocol Description

This research study involves a class of drugs known as anti-TNF agents for the treatment of rheumatoid arthritis (RA). Humira (adalimumab) and Enbrel (etanercept) have both been approved by the U.S. Food and Drug Administration (FDA) for the treatment of RA.  This study aims to look at the specific mechanism of action of these two drugs on the immune cells involved in RA.  There are a number of immune cells believed to be responsible for the immune system “attack” in RA.  Two of these are the B cells and the T cells. While it is known that the anti-TNF drugs target the T cell response, recent evidence suggests that the drugs may also have an effect on the B cells.  This study aims to explore the effect of anti-TNF agents on B cells in particular.

Eligibility Criteria

Patients with rheumatoid arthritis (RA)

Primary Investigator(s)

  • Meggan Mackay, MD

Contact Information

Andrew Shaw, BS (516) 562-2591 anshaw@nshs.edu

Last Update

May 4, 2010
top
  • Share this Page
  • Bookmark this Page
  • Toggle Text Size
  • Print this Page
Search Arthritis:
top
top